Firstly, based on immunohistochemical requirements of tumor specimens for detecting PD-L1 expression, the patients included in the present study were mainly at stage I–III; therefore, cases at stage IV were quite limited, which was also the limitation of the previous studies. This evidence concerns the gene CD274 and neoplasm.